ARVN

ARVINAS, INC. (ARVN) - Q3 2025 10-Q Summary

Business Context and Reporting Period

Arvinas, Inc. is a clinical-stage biotechnology company developing targeted protein degradation therapies using its PROTAC platform. This report covers the quarterly period ended September 30, 2025. The company is currently advancing multiple clinical programs, including ARV-102 (neurodegenerative), ARV-393 (lymphoma), ARV-806 (solid tumors), and vepdegestrant (breast cancer), alongside preclinical candidates.

Key Financial Metrics

Note: Cash and marketable securities as of Sept 30, 2025, totaled $787.6 million ($101.5M cash + $686.1M marketable securities).

Material Changes vs. Prior Period

• Revenue Decline (QoQ): Q3 2025 revenue decreased 59% compared to Q3 2024, primarily due to the completion of the Novartis technology transfer period (which ended in Dec 2024) and the termination of the Bayer collaboration in August 2024. This was partially offset by a $20.0 million milestone recognition from Novartis.
• Improved Net Loss (9M): The net loss for the nine months ended Sept 30, 2025, improved significantly to $13.4 million from $153.8 million in the prior year. This improvement was driven by a $150.2 million revenue increase from an accounting estimate change regarding the Pfizer vepdegestrant collaboration (removal of two Phase 3 trials) and reduced operating expenses.
• Expense Reduction: Operating expenses decreased due to workforce reductions (33% in Q2 2025 and an additional 15% in Q3 2025) and the absence of a $43.4 million lease termination loss recorded in Q3 2024.
• Share Repurchases: The company initiated a $100 million share repurchase program in September 2025, repurchasing approximately 2.56 million shares for $20.2 million during the quarter.

Guidance, Outlook, and Management Commentary

• Liquidity: Management believes current cash, cash equivalents, and marketable securities ($787.6 million) are sufficient to fund operations into the second half of 2028.
• Restructuring: The company expects to achieve annual operating cost savings of $100 million on a run-rate basis following workforce reductions. The September 2025 reduction is expected to be substantially completed by Q1 2026.
• Commercialization Strategy: Arvinas and Pfizer agreed to jointly select a third party for the commercialization and potential further development of vepdegestrant, as Arvinas will not build its own commercial infrastructure for this asset.
• Clinical Milestones:
  • Vepdegestrant: FDA accepted the NDA with a PDUFA action date of June 5, 2026, for the ESR1-mutant breast cancer indication.
  • ARV-102: Positive Phase 1 data presented showing brain penetration and LRRK2 degradation; Phase 1b in PSP planned for H1 2026.
  • ARV-806: Phase 1 enrollment ongoing; initial data expected in 2026.
• Risks: Significant risks include the potential disruption of FDA operations due to government shutdowns and workforce reductions, the uncertainty of realizing cost savings from restructuring, and the need for additional capital if clinical timelines extend.

Investor Verification Checklist

• Accounting Estimate Change: Verify the impact of the $150.2 million revenue acceleration related to the Pfizer collaboration and the removal of Phase 3 trials.
• Restructuring Execution: Monitor the realization of the projected $100 million annual run-rate cost savings and the completion of the 15% workforce reduction by Q1 2026.
• Share Repurchase Utilization: Track the remaining $79.8 million authorization under the new buyback program and its impact on cash runway.
• Third-Party Commercialization: Confirm the selection of a third-party partner for vepdegestrant commercialization and the associated terms.
• Regulatory Environment: Assess the potential impact of FDA staffing reductions and government shutdowns on the June 2026 PDUFA date for vepdegestrant.